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Abstract: Bone diseases include a wide group of skeletal-related disorders that cause mobility
limitations and mortality. In some cases, e.g., in osteosarcoma (OS) and metastatic bone cancer,
current treatments are not fully effective, mainly due to low patient compliance and to adverse
side effects. To overcome these drawbacks, nanotechnology is currently under study as a potential
strategy allowing specific drug release kinetics and enhancing bone regeneration. Polymers, ceramics,
semiconductors, metals, and self-assembled molecular complexes are some of the most used nanoscale
materials, although in most cases their surface properties need to be tuned by chemical or physical
reactions. Among all, scaffolds, nanoparticles (NPs), cements, and hydrogels exhibit more advantages
than drawbacks when compared to other nanosystems and are therefore the object of several studies.
The aim of this review is to provide information about the current therapies of different bone diseases
focusing the attention on new discoveries in the field of targeted delivery systems. The authors hope
that this paper could help to pursue further directions about bone targeted nanosystems and their
application for bone diseases and bone regeneration.
Keywords: bone diseases; bone regeneration; nanotechnology; targeted delivery systems; calcium
phosphate
1. Introduction
Bone is one of the most important organs of the human body which sustains and protects
other organs, produces blood cells, and regulates hormones [1]. It is composed of a matrix that
includes proteins such as collagen, proteoglycans, and lipids, and a mineral phase, generally known
as hydroxyapatite (HA) Ca10(PO4)6(OH)2 [2]. Besides the mineral and protein component, cells,
macromolecules, and blood vessels could also be found in bone. Among such cells, some of them
can enhance the healthy structure of bone, i.e., osteocytes, implicated in the signal transduction of
mechanical stimuli, osteoblasts, delegated to the secretion of collagenous proteins which constitute
the bone material, and osteoclasts, that secrete acids and proteases and degrade the mineralized
tissue. Furthermore, on the osteoblast surface, the receptor activator of nuclear factor kappa-B ligand
(RANKL) is bound, which is a protein molecule that activates osteoclasts and is able to facilitate the
communication between osteoclasts and osteoblasts. In the case of RANKL overexpression, a large
amount of degenerative bone disease could occur [3].
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Bone diseases include a wide group of skeletal-related disorders that cause mobility limitations
and mortality. The treatment of bone diseases requires oral and bolus administration of high doses of
drug in order to reach effective drug concentrations in the bone tissue. Such high drug concentrations
in blood may induce secondary adverse effects in other organs and tissues [4–6]. Therefore, there is a
critical necessity to optimize the delivery of effective drug concentrations to the bone disorder site
without reaching toxic levels in blood. The local administration of drugs in bone tissue diseases and
disorders is an area of active research.
Nanotechnology is an important research area, having one of its important applications in
biomedical sciences and, among these, targeted drug delivery is one of the most studied. Nanosystems
used as vehicles should observe a particular affinity for bone inorganic material but should also
be able to target the site of bone disease and prolong drug release. The material forms used for
this aim include a range of nanoscale compounds like polymers, ceramics, semiconductors, metals,
and self-assembled molecular complexes. In general, such nanomaterials should be able to deliver drugs,
but also different biomolecules which could allow specific release kinetics and biodistribution and
enhance bone regeneration. Several advantages are connected to the use of nanometer sized carriers,
i.e., high volume to surface ratios which allow efficient drug adsorption, capability of enhancing
drug solubility and chemical stability in biological media, ease of surface functionalization to address
specific requirements, enhanced transport across cell membrane reducing drug removal from the
body, controlled dissolution rates/drug bioavailability, and size similar to natural bone components
(e.g., HA).
Furthermore, to optimize nanocarriers for specific functions, the surface properties of
nanomaterials could be tuned by physical or chemical adsorption. For example, different proteins can
be adsorbed on the surface promoting osteoblasts functions and an increase of surface charges could
have a great impact on the transport to the bone [7]. Furthermore, a better ability to bind calcium ions
of HA could be obtained in the presence of negatively charged calcium phosphate (CaP) coatings. Also,
several nanomaterials like superparamagnetic iron oxide nanoparticles (SPIONs), gold nanoparticles
and quantum dots may be detected by either magnetic resonance (MRI), computer tomography, and/or
photoluminescence imaging, which allow the monitoring of drug delivery [8].
Despite the fact that nanotechnology has been investigated as a potential strategy to reduce side
effects related to the therapies [5,9], most investigated systems did not surpass the transition from
laboratory research to clinical application. Therefore, only a few formulations have been approved by the
U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment
of bone cancer. The most relevant example is represented by Mepact® (Millennium, Cambridge,
MA, USA), a liposomal formulation of non-pegylated mifamurtide (muramyl tripeptide phosphatidyl
ethanolamine, MTP-PE) approved by EMA in 2009 for the treatment of osteosarcoma (OS) [10,11].
For the treatment of osteomyelitis, there are five antibiotic-loaded poly(methyl methacrylate) (PMMA)
bone cements approved by FDA: Simplex® P (Stryker Howmedica Osteonics, Mahwah, NJ, USA),
Palacos® G (Zimmer, Warsaw, IN, USA), SmartSet® GHV and SmartSet® MHV (Depuy Orthopaedics,
Inc., Warsaw, IN, USA) and the Prostalac® prosthesis (DePuy Orthopaedics, Inc.). Furthermore,
PMMA antibiotic loaded beads products (Septopal®) are widely used and available in Europe [12].
CaP cements (CaPCs) were approved by FDA in 1996 for the treatment of maxillofacial/craniofacial
defects or in case of vertebroplasty. Three formulations are commercially available: Alpha-BSM®
(Etex Corporations, Cambridge, MA, USA), Bone Source® (Striker How medica Osteonics, Rutherford,
NJ, USA), and Skeletal repair systems® (SRS) (Norian Corporation, Cupertino, CA, USA) [13].
Overall, the clinical translation of nanomedicines is hindered by the difficulty to assess reproducible
manufacturing, characterization and scale-up, and most of all, to ensure in vivo stability and safety.
Moreover, disease heterogeneity and clinical trials strategies require further learning, and regulatory
rules require an adequate regulatory background [14].
The aim of this review is to summarize the most recent progress of bone targeted drug delivery
systems for the treatment of bone diseases like bone metastases, OS, osteoporosis, osteomyelitis,
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and bone regeneration. In the first part, we introduce some information about the pathogenesis
and current therapies of the above-mentioned pathologies, including advantages and disadvantages,
while in the second part, new discoveries about targeted delivery systems are discussed. It is thus
hoped that the discussion herein presented could allow the pursuit of further directions about bone
targeted drug delivery and its application for bone diseases and bone regeneration [1].
2. Bone Disease: Pathogenesis and Current Therapies
2.1. Bone Metastases
Bone is a frequent site of metastasis, particularly due to breast and prostate cancer, while it is less
common as a site of primary cancer, especially in adults.
Based on the primary mechanism of interference with normal bone remodeling, bone metastasis
can be classified in three types as reported in Table 1.
Table 1. Bone metastases characteristics [15].
Types Pathophysiology Primary Cancer Sites
Osteolytic Destruction of normal boneby ostoclasts
Multiple myeloma, melanoma, non-small cell lung cancer,
non-Hodgkin lymphoma, thyroid cancer or Langerhans-cell
histiocytosis, breast cancer, renal cell carcinoma
Osteoblastic Deposition of new boneby osteoblasts
Prostate cancer, small cell lung cancer, Hodgkin lymphoma
or medulloblastoma
Mixed Osteolytic and osteoblastic lesions orboth types present in the same lesion
Breast cancer, gastrointestinal (GI) cancer and
squamous cancer
Bone metastases are the major cause of morbidity, characterized, for example, by severe pain,
pathologic fractures, bone marrow aplasia, and hypercalcemia. Therefore, the treatment of metastasized
cancers in bone is important for patients in providing prolonged survival rates. In Table 2, the most
used chemotherapeutic agents are represented, with a focus on their mechanism of action and common
side effects.
Table 2. Common drugs and therapeutic techniques for the treatment of bone metastases.
Agent Mechanism of Action Side Effects
Bisphosponates
(BPs)
Inhibition of bone demineralization by the
interruption of enhanced osteolysis and
tumor growth [16]
Fever, arthralgia, myalgia, anemia,
nausea and peripheral edema.
Osteonecrosis of the jaw (rare, difficult to
establish casative evidence) [17]
Tetracyclines Inhibition of matrix metalloproteinases(MMPs) involved in bone metastasis [17]
Dose-limiting toxicity e.g., fatigue and nausea,
development of resistance [18]
Generally well tolerated in adults
Denosumab Inhibition of RANKL which prevents thedevelopment of osteoclasts
Similar to those exhibited by BPs,
but reversible after treatment interruption [15]
Cabozantinib
Inhibition of vascular endothelial growth
factor receptor-2 (VEGFR2), MET, KIT and
mutationally activated RET [15]
Fatigue, diarrhea and palmar-plantar
erythrodysesthesia syndrome [19]
Radionuclide
therapy
Systemic administration of radioisotopes,
but the mechanism of pain relief is
uncertain [20]
Myelosuppression and pain flare [15]
Ablation
Use of chemical agents (ethanol, acetic acid)
or local deposition of some form of energy
(e.g., for radiofrequency and cryoablation)
to destroy tumor cells [21]
Neurologic injuries, neuropathic pain and
infection in the treatment area (especially for
radiofrequency and cryoablation) [22]
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Surgery is indicated only in a few cases, such as long bone fractures or nerve compression,
while stereotactic surgery is considered an emergent treatment for the metastases of vertebral bodies
and the spinal cord. This therapy shows several advantages (no needs to irradiate large segment of the
column and rapidity of the treatment), but currently, there is a low quality of literature, there are no
randomized controlled studies, and it is more expensive than conventional radiotherapy [23]. For these
reasons, it is necessary to find drug delivery systems to reduce side effects and to increase patient
compliance. Furthermore, to obtain a system which can be systemically administered and reach the
bone mineralized tissue, it is necessary to focus on the dimension of the carrier because it has to cross
the blood-bone marrow barrier, including the clefts of bone marrow sinusoidal capillaries which have
a diameter of about 80–100 nm [24].
2.2. Osteosarcoma
OS is the commonest bone sarcoma, characterized by the production of osteoid and bone by
malignant spindle cells, which affects primarily 10–20 year-old patients. This type of tumor develops
mainly in the metaphyseal regions of the distal femur, proximal tibia and proximal humerus, although it
can origin in any bone. An OS grows in a radial manner, forming a ball-like mass. Then, it penetrates
the bony cortex and it compresses the surrounding muscles, forming a pseudocapsular layer called the
“reactive zone” in which nodules (also known as “satellites”) may also arise which are microextensions
of the primary mass. Patients typically complain a dull and aching pain that could last for several
months and suddenly becomes more severe probably due to tumor penetration of cortical bone or to
pathologic fracture [25].
Based on its histologic, radiographic, and clinical features, OS can be classified in two groups:
intramedullary and cortex-associate (surface) subtypes as summarized in Table 3.
Table 3. Classification of Osteosarcoma (OS).
Types Subtypes Frequency
Intramedullary
Conventional (osteoblastic/chondroblastic/fibroblastic) 80%
Telangiectatic <4%
Low-grade 1–2%
Small cell 1.5%
Cortex-associated
Parosteal 1–6%
Periosteal 1–2%
High-grade surface <1%
Currently, chemotherapy is essential in the treatment of OS, because it can decrease the size of
the primary tumor through the reduction of its neovascularization and of the number of pulmonary
metastasis or delay their appearance. Common treatments consist in a combination of therapies that
include preoperative chemotherapy followed by the surgical resection of the primary tumor plus the
addition of postoperative chemotherapy. Preoperative chemotherapy leads to necrosis of the primary
tumor and is a first treatment of micrometastasis in order to facilitate surgical resection.
Drugs used in this step are doxorubicin (DOX), cisplatin, ifosfamide (also in combination with
mesna that prevents hemorrhagic cystitis) and high dose methotrexate with leucovorin as calcium
rescue used to prevent myelosuppression and mucositis [26]. The combination of different drugs could
avoid chemoresistance and increase the degree of tumor necrosis. In Table 4 [25], the mechanism of
action and the side effects of the different chemotherapeutic agents are reported.
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Table 4. Chemotherapeutic agent used in the treatment of OS [25].
Agent Mechanism of Action Side Effects
DOX
Intercalation at points of local uncoiling of the
DNA double helix and inhibition of
DNA/RNA synthesis
Cardiomyopathy, emesis, alopecia,
mucositis, myelosuppression
Cisplatin
Formation of DNA cross-links with inhibition
of the synthesis of the tumor DNA and
denaturation of DNA double helix
Acute/chronic renal failure, ototoxicity,
emesis, myelosuppression, alopecia,
hypomagnesemia
Ifosfamide, with mesna Cross-linking of DNA strands with inhibitionof DNA/protein synthesis
Hemorrhagic cystitis, renal failure,
myelosuppression, alopecia, emesis,
encephalopathy
High-dose methotrexate (MTX),
with leucovorin calcium rescue
Inhibition of purine/thymidylic acid synthesis
by binding dihydrofolate reductase
Renal failure, mucositis,
myelosuppression, nervous system
effects (rare)
Surgical resection is performed 3–4 weeks after the last dose of preoperative chemotherapy,
while postoperative chemotherapy begins 2 weeks later when the tumor necrosis is found to be ≥90%
at the time of surgery. In some cases, radiation therapy is used in the treatment of OS, but is only
palliative because this type of tumor is highly resistant to radiation.
For this reason, the aim of current research is to improve and develop more target-selective
treatments with the aim of enhancing overall long-term survival and reducing side effects.
2.3. Osteoporosis
Osteoporosis is a common bone disease in which low bone mass and microarchitectural
deterioration of bone tissue are frequent characteristics with an increment of bone fragility and
susceptibility to fracture. It is often underdiagnosed and not treated with disease-specific medication.
Potential risks for secondary osteoporosis are endocrine disorders, hypogonadism, inflammatory
disease, bone marrow disorders, immobilization, malabsorption, low body weight, defective synthesis of
connective tissue, or regular intake of drugs with side effects on bone metabolism [27]. Current therapies
provide for the interruption or the slowdown of the increased resorptive activity in order to
prevent further deterioration. Nitrogen-containing BPs (N-BPs) and the human monoclonal antibody
denosumab are very effective in slowing this bone decay. Despite their common end results, there are
important differences between these two classes of antiresorptives, such as mode of action, rebound
bone resorption, and adverse event profiles (Table 5) [28].
Table 5. Characteristics of the two main classes of antiresorptives [28].
Drug Advantages Disadvantages
N-BPs
Bone selectivity, inexpensive, longtime use,
apoptosis of osteoclasts inductors
(but don’t eliminate them)
Effects on renal functions, atypical femoral
fractures (osteonecrosis of the jaw),
GI adverse effect, acute phase reactions
Denosumab
No effect on renal function, low frequency
of administration, no bone accumulation,
reversible effects
No bone selectivity, atypical femoral
fractures, increased risk of infections,
parenteral administration, reduction in
bone formation, rebound bone resorption
Newer antiresorptives include cathepsin K inhibitors, which act on the cysteine protease cathepsin
K, highly expressed in osteoclasts and essential for the digestion of cartilage and bone collagenous
matrix. Additionally, another class used in osteoporosis therapy is represented by selective estrogen
receptor modulators (SERMs) and tissue-selective estrogen complexes (TSECs).
In Table 6, the most representative drugs of these classes are discussed.
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Table 6. Characteristics of newer antiresoprtives and selective estrogen receptor modulators (SERMs) [28].
Class Drug Characteristics
Cathepsin K
inhibitors Odanacatib
Ability to decrease the rate of bone resorption,
preserving other osteoclasts functions
Orally active, weekly administered
Phase III fracture clinical trial
SERMs
Raloxifene Ability to decrease the risk of vertebral fractures by 30%First FDA approved SERM
Bazedoxifene in
association with TSECs
Treatment of moderate/severe hot flashes associated with menopause
Approved by FDA in 2013 and in the European Union in 2009
(to be used alone)
Lasofoxifene Double event rate for venous thromboembolic events
Nevertheless, antiresorptives are helpful only in bone-forming, but the faulty structure remains.
Currently, parathyroid hormone (PTH) is the only available treatment with the potential to reconstruct
skeleton. In fact, PTH is capable of stimulating both bone formation and resorption. An alternative
to PTH administration is represented by calcium-sensing receptor antagonists (also called calcilytics)
which can stimulate the secretion of PTH from the parathyroid glands. Different studies report that
these compounds act by reproducing the hypersecretion pattern of the hyperparathyroid state instead
of that of pulsatile waves of circulating PTH required for osteoanabolics effects [29]. Another class of
drugs attracting the attention of researchers is represented by sclerostin inhibitors. Sclerostin is an
antagonist of Wnt signaling and is an important negative regulator of bone formation. It is produced
by the gene SOST, and it resulted that sclerostin gene knock-out mice have increased bone formation
and strength. The main characteristics of romosozumab and blosozumab, two sclerostin inhibitors
currently under investigation, are reported in Table 7.
Table 7. Characteristics and disadvantages of sclerostin inhibitors [28].
Drug Origin Characteristics Disadvantages
Romosozumab Humanized mousemonoclonal antibody
Increment of lumbar spine and
hip bone mass density during
the first year of treatment
Phase II studies
Benign safety profile need to be confirmed
Probable development of antibodies against them
Probable risk of vascular calcification
Parenteral administration
Blosozumab Humanized mousemonoclonal antibody Under investigation
Strontium ranelate has been promoted as a bone agent of dual action mode, though histomorphometric
data showed no significant anabolic action and limited effects on bone resorption. For this reason,
the use of strontium ranelate in Europe is limited to the treatment of severe osteoporosis in patients
without a history of cardiovascular disease [28].
2.4. Osteomyelitis
Osteomyelitis is a bone infection/inflammation, particularly common among the elderly, diabetics,
children and people from the Third World Countries. It is caused by pyogenic bacteria living in healthy
oral flora, but in some cases, it is also due to fungi infection. For example, Haemophilus influenzae,
Brucella suis, Mycobacterium tuberculosis, Mycobacterium ulcerans, and Fusobacterium nucleatum are some
of the commonest pathogens. Among all, staphylococcal infections, mostly caused by Staphylococcus
aureus and Staphylococcus epidermidis, are the major cause of osteomyelitis. Then, a large number
of factors, like bacteria, pH change, local edema, vascular obstruction, and leukocyte collagenase,
contribute to disease progression. Osteomyelitis is largely widespread in the facial skeleton because
it is more accessible to external pathogens and microorganisms. It is also a complication that could
occur after orthopedic, maxillofacial surgeries and dental extractions. Timely treatment is required
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to prevent its diffusion to other sites. Common therapies include the administration of antibiotics
by endovenous route until 2–6 weeks (followed by a 6-month course of oral antibiotics when there
is a chronic infection) and surgical removal of necrotic bone. Several downsides are related to the
conventional therapeutic approach, e.g., side effects due to antibiotic systemic administration and low
concentration of the therapeutic agent around the site of infection, which could induce resistance and
bone loss that often requires the insertion of implants or prostheses. A widely used option for the local
drug delivery of antibiotics is represented by PMMA cements or beads loaded with hydrophilic drugs
such as gentamicin sulfate (GS), ceftriaxone, tobramycin (TOB), and vancomycin, although numerous
clinical drawbacks like non-biodegradability, need to be surgical removed and exhibition of a burst and
inconsistent release profile are connected with their use. For these reasons, it is important to develop
locally targeted and minimally invasive therapies for the treatment of osteomyelitis [30–32].
2.5. Bone Regeneration
Bone possesses the ability to regenerate itself in response to injury, requiring some of biological
events of bone induction and conduction which involve a large amount of different cell types and
intracellular and extracellular molecular-signaling pathways. Many studies have also confirmed that
several growth factors may regulate different phases of bone fracture repair. Among these, the most
important are the bone morphogenetic protein (BMP), the transforming growth factor-β (TGF-β),
the fibroblast growth factor (FGF), the vascular endothelial growth factor (VEGF), the platelet-derived
growth factor (PDGF), the insulin-like growth factor (IGF), the interleukin-1 (IL-1), and the tumor
necrosis factor (TNF) [33]. Generally, most bone injuries (in particular fractures) can heal without the
formation of scar tissue, restoring the pre-existing properties of the bone.
However, there are different cases, e.g., orthopedic and oral/maxillofacial surgery, in which bone
regeneration is very important, or cases in which the regenerative process is compromised, such as in
vascular necrosis and osteoporosis.
Currently, several treatment methods are available for previously discussed cases, which could
be used alone or in combination. Standard regimens include distraction osteogenesis and bone
transport or the use of autologous bone grafts, allografts, bone-graft substitutes or growth factors.
In particular, during distraction osteogenesis and bone transport, bone regeneration is induced between
the gradually distracted osseous surfaces by the use of external fixators and the Ilizarov technique [34],
which provides a versatile fixation by the combination of unreamed intramedullary nails and external
monorail distraction devices, or intramedullary lengthening devices. In this way, during distraction,
regenerate bone arises between the entire cross-sections of each distracted bone surface [35]. In any
case, these methods are technically difficult and exhibit several drawbacks. Bone grafting, and in
particular autologous bone, is a common surgical procedure because it brings together all properties
desired in a bone graft material, i.e., osteoinduction, osteogenesis, and osteoconduction. This method
offers several advantages like histocompatibility and non-immunogenicity which are able to reduce
to a minimum immunoreactions and transmission of infections, but at the same time there are some
complications that could represent a discomfort for the patient. An alternative is represented by
allogenic bone grafting, obtained from human cadavers or living donors, which could bypass the
problems of the previous method but, at the same time, exhibits low osteoinductive properties, issues of
immunogenicity, rejection reactions and the possibility of infection transmission. Bone-graft substitutes
are other alternatives to autologous and allogenic bone grafts, which consist of a scaffold made of
synthetic or natural biomaterials, like collagen and its composites [36], HA, CaPCs, and glass ceramics,
able to promote bone regeneration [37]. The ideal materials for bone fracture repair should have
some characteristics, such as good biocompatibility, appropriate biodegradability, good mechanical
properties, osteoinductivity, and osteoconductivity. A 3D-porous structure and the possibility to be
easily sterilized should be desirable. Examples of currently used materials for bone fracture repair
also include bone, bone cements, metal, ceramic, and polymer. All of them exhibit advantages and
disadvantages, some of which are depicted in Table 8 [33].
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Table 8. Traditional materials used for bone repair [33].
Material Type of material Advantages Disadvantages
Bone
Autologous bone Biocompatible with high bonefusion rate Limited sources
Allogenic bone Relatively high bone fusion rate Immune rejection
Heterologous bone Wide variety of sources Severe immune rejection andpoor bone formation
Bone
cement
Non-bioactive
bone cement Easy fit, good hardening properties
Poor biocompatibility,
non-osteoinductive,
non-osteoconductive
Bioactive bone cement High strength, stability and boneinduction activity
Insufficient mechanical
properties, expensive
Metal
Stainless steel Easy processing, inexpensive High stiffness,poor biocompatibility
Titanium alloy Biocompatible, corrosion resistance Poor wear resistance
Cobalt chromium alloy Biocompatible, high corrosionresistance Low ductility
Ceramic
Aluminium oxide Inertness, high corrosion resistance Possible local stress
Apatite-wollas-tonite
glass ceramic Good biological activity Brittleness, poor flexibility
Polymer
Poly(lactic-co-glycolic)
acid (PLGA) Biocompatible, degradable Possible disruption
PMMA Corrosion resistance, easy fit Poor biocompatible
Chitosan
High degradable and biocompatible,
porous structure,
good mechanical properties
Non-osteoinductive,
inadequate bone formation
ability, low solubility
Alginate Easy to manipulate, non-toxic,biodegradable, less expensive Low mechanical stability
3. Drug Delivery Systems for Bone Diseases
Among the broad spectrum of nanotechnology-based drug delivery, several systems are used
for the treatment of bone disease. Here, we propose a brief overview of the commonest types of
nanosystems exploited for this aim.
• Extracellular vesicles (EVs): proposed for their ability to load proteins and nucleic acid in various
fields such as oncology and regenerative medicine [38,39].
• Liposomes: spherical vesicles with an aqueous core surrounded by a single or multiple bilayer
membrane, proven to be suitable tools also in several bone diseases [40].
• Microspheres: generally made of natural, semisynthetic, and synthetic polymers, frequently
applied in anticancer therapy [41,42].
• NPs: solid, colloidal particles of different materials which can be functionalized or coated to
improve stability and receptor binding [43].
• Beads: frequently used as bone drug carriers, generally based on alginate, chitosan, gelatin and
cellulose [44,45].
• Dendrimers: nanosized synthetic polymeric macromolecules composed of a central core with
branching units that can provide cytotoxicity [46,47].
• Conjugates: especially polymer-drug [48] and lipid-drug types, exploited in bone diseases [49].
• Cements: obtained by mixing solid and liquid parts until a viscous paste is formed, used both as
bone filler during surgery and as drug carrier [2,50,51].
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• Ceramics: inorganic non-metallic solids obtained by heating [52], includingβ-tricalcium phosphate
(TCP), HA, and mesoporous silica [53].
• Nanodiamonds: carbon-based nanomaterials which exhibit a large surface area and could be
functionalized to conjugate various compounds or drugs, suitable as photoluminescent probes [54].
• Nanocrystals: usually stabilized by surfactants and/or polymers to prolong the circulating time in
the blood and facilitating tumor accumulation [55].
• Nanohybrids: which combine the mechanical and thermal stability of the inorganic component
and the ease of processability of the organic one (e.g., clay-based, carbon-based or metal/metal
oxide based nanohybrids) [56,57].
• Polymeric gels: solid–liquid systems with polymeric matrix broadly crosslinked forming a 3D
network of particular interests for biomedical applications [58].
• Matrices: consisting in homogenous dispersions of solid drug in a polymer mixture [59].
• Nanocapsules: systems with a liquid/solid core with a protective coating which delays the release
of the entrapped active compounds [60].
• Implants: man-made materials (metals, polymers or ceramics) embedded in the human body to
repair or replace damaged tissues [61,62].
• Scaffolds: biocompatible templates which are similar to a platform and promote the attachment
and the growth of cells, thus used for tissue regeneration and surgical repairs [63].
• Nanoplatforms: biocompatible and biodegradable engineered systems based on NPs, liposomes,
micelles, and dendrimers, capable to load both hydrophilic and lipophilic drugs and molecules,
making them attractive systems mainly in cancer therapy [64].
In the following paragraphs, we propose a focus on the above-mentioned drug delivery systems
organized according to main bone diseases. It is noteworthy that, to date, clinically approved
nanotechnology-based therapeutic agents concern those known as “first generation agents” which are
composed by liposomes or polymers, with no active targeting, and containing only one type of drug.
3.1. Bone Metastases
In the last decades, different drug delivery systems have been developed for bone metastases.
Many attempts have been centered on NP drug delivery systems, like HA NPs, liposomes, and micelles,
with the aim of increasing their permeability to the blood–bone marrow barrier and the retention time.
For example, in a recent study (2017), some researchers developed water-in-oil (W/O) microemulsion
in which a cisplatin prodrug (DSP) was included in polymer nanoparticles (CPNs) functionalized with
alendronate (ALN) to obtain a selective accumulation in the bone metastatic lesion and a prolonged
drug circulation time [65].
Another type of polymeric NPs (PNs) with high bone affinity were prepared by Hirano et al.
(2017) using poly(ethylene sodium phosphate) (PEPn Na). These systems show low cytotoxicity with
high colloidal stability (at least 1 week) [66].
In 2017, Chu et al. designed a novel bone-targeting NP combining the anti-osteoporosis property
of BPs and the similarity of CaP sediments to HA. In this study ALN was conjugated to PEG 2000
(ALN-PEG2000-ALN) and then anchored to the surface of CaP NPs with the aim to prolong the
circulation time and obtain a selective delivery to the bone [67].
Another research carried out by Chaudhari et al. (2012) involved the development of zoledronate
(ZOL) anchored PLGA NPs loaded with docetaxel (DTX) in order to combine the cytotoxic effects of
both DTX and ZOL. In vitro studies showed enhanced activity. Moreover, in vivo animal study using
technetium-99m radiolabeling indicated prolonged blood circulation half-life, less liver uptake, and a
higher retention of ZOL targeted NPs at bone site [68].
Further, different studies suggest that osteocytes (which secrete HA) are also involved in
the development of cancer bone metastasis. It is possible that these cells are able to control the
activity of bone metastasis and osteoclastogenesis through the expression of some growth factors
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(e.g., RANKL). So, the inhibition of osteocyte-mediated osteolysis represents a probably better
approach for bone tumor treatment. For this reason, Qiao et al. (2017) developed ZOL-anchored
bimodal mesoporous silica covered gadolinium (III) NPs loaded with plumbagin (PL, a medicinal
plant-derived naphtoquinone with anticancer properties [69]) to detect and treat bone metastasis at an
early stage. Results demonstrated that developed NPs could regulate osteoclastogenesis, and they
could also be applied for other bone related disease, like osteoporosis and osteoarthritis, in order to
achieve theranostic effects [70].
Another interesting approach is focused on peptides with aspartic acid (ASP) repeating units
for bone-targeting delivery. These peptides are negatively charged and able to bind calcium ions on
the surface of HA. Additionally, amino acids exhibit a lower rate of cytotoxicity because they can be
degraded by enzymes and cleared from the body after the binding with HA. For this reason, Ke et al.
(2017) developed a dual-targeting liposomal system with Asp8 and folate that could target tumor cells
in the bone. [71].
Another research carried out by Anada et al. (2009) was based on the development of DOX-loaded
CaP-binding liposomes. They synthesized an amphipathic molecule bearing a BP head group with
high affinity and selectivity for HA. The results showed a reduction of the number of tumor cells
with above-mentioned systems; for this reason, they could be used for different bone-related diseases
(e.g., osteoporosis, rheumatoid arthritis, and multiple myeloma) and loaded with many drugs [72].
Dendrimers are other promising drug carriers. Yamashita et al. in a recent study (2018) developed
bone-targeting dendrimers in which ALN was covalently linked to a PEG-conjugated polyamidoamine
(PAMAM) dendrimer (PEG-PAMAM-ALN) for bone targeting of MTX. After intravenous injection in
mice, MTX-loaded PEG-PAMAM-ALN were effectively distributed to the bones and suppressed the
number of tumor cells localized in the bone (Figure 1) [73].
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Figure 1. Schematic representation of methotrexate (MTX)-encapsulated dendrimers for the treatment
of bone metastasis which allow the suppression of tumor cells in mice.
Previously, Clementi et al. (2011) investigated a pegylated dendrimer glutamic acid (GLU)
(H2N-PEG-β-GLU-(β-GLU)2-(COOH)4) coupl d with paclitaxel (PTX) and ALN with the aim of
obtaining a better targeting and enhanced activity [74]. Resul s r ported that PTX-PEG-ALN were
nontoxic and showed an IC50 similar to free PTX with increased tumor cell killing efficacy [75].
Another tool to treat bone metastasis is represented by drug-conjugates, a class of carriers which
can protect drugs from too rapid degradation and interactions with other drugs or with the biological
environment and enhance the absorption of the drugs into the tissues. In 2015, Ye et al. synthesized
ALN-monoethyl adipate-(hydrazine)-DOX conjugate (ALN-MA-hydrazine-DOX) to deliver DOX to
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the bone. The results showed a high absorption capacity of the conjugate and a high release rate in
the 5.0–6.0 pH range [76]. Also, ALN-MA-hydrazine-DOX conjugate exhibited high cytotoxicity on
wild-type and DOX-resistant tumor cells, without systemic toxicity [77].
In 2011, Zheng et al. conjugated catalase with 3,5-di(ethylamino-2,2-bisphosphono) benzoic acid
(Bip) (catalase-Bip), that is a derivate of BPs, with PEG (PEG-catalase) or with both Bip and PEG
(PEG-catalase-Bip). Catalase was chosen because it is an enzyme involved in the degradation of
hydrogen peroxide and other reactive oxygen species (ROS) which play an important role in the
development of tumor metastasis, osteoclast activation, and osteolysis [78]. For this reason, through
chemical modification, it could be used as therapeutic agent in bone diseases. At the same time,
PEG-conjugation could increase the retention time of catalase and reduce the uptake of the enzyme by
liver [79].
In 2004, El-Mabhouh et al. focused their attention on the synthesis of two types of BPs conjugates
with 5-fluorouracil as a chemotherapy agent and with diethylenetriaminepentaacetic acid (DTPA) as a
carrier of cytotoxic radionuclide. Thereby, 99mTc-labeled BPs conjugates with DTPA and 5-fluorouracil
showed a rapid clearance from the blood and many other tissues, but a substantial retention of the BPs
in bone [80].
Nanoplatform and cement are less common systems, although they can be considered as alternative
tools for the treatment of bone metastasis. Sun et al., in a recent work (2019), developed a nanoplatform
with gold nanorods enclosed inside mesoporous silica NPs (Au@MSNPs) and conjugated with ZOL.
In this project, researches decided to add the gold nanorods to the system, as photothermal agents,
because different studies suggest that photothermal therapy (PTT) is effective in order to ablate
several types of cancers, under near-infrared (NIR) laser irradiation. Moreover, hyperthermia could
promote the efficiency of chemotherapy [81]. Au@MSNPs-ZOL showed promising results like good
bone-targeting capacity and ability to inhibit osteoclast differentiation while promoting osteoblast
one. Furthermore, the combination with NIR could inhibit tumor growth, inducing cancer cell
apoptosis even if further studies need to consider the overall bone metabolism balance [82]. In 2011,
Lopez-Heredia et al. developed a local drug delivery system, carried with chemotherapeutic agents
using CaPCs, which are biocompatible materials, frequently used for bone filling applications and
with fewer-invasive surgical procedures. Furthermore, CaPCs, compared with PMMA bone cements,
exhibit better properties, e.g., crystalline affinity to bone tissue and the possibility to be resorbed and
replaced with bone tissue in vivo. PTX was chosen as chemotherapeutic agent and was loaded onto
CaPC discs by absorption. From the results, it appeared that the slow and gradual release of PTX from
CaPCs was effective against MDA and OST cells. Full drug release was expected to be reached after
cement degradation, providing a prolonged local delivery effective against the formation of secondary
metastasis [83].
Concluding, we can assume that nanomedicine has developed several therapeutic modalities
for bone metastases. Among the several NPs and liposomes and dendrimers described in literature,
only some of them have been used in preclinical animal models showing increased prolonged circulation
times and bone tissue affinity with consequent increased drug efficacy and decreased toxic side effects,
whilst most experimental results consisted in in vitro studies.
Bone cements, even if already used in surgical implants, are new and interesting tools that are
currently evaluated to be exploited for drug delivery, but further attention should be given to evaluate
their safety and effectiveness.
3.2. Osteosarcoma
Recent studies have involved the use of EVs and in particular exosomes, as potential drug
delivery systems to the bone. It seems that EVs secreted by tumor cells are involved in cancer
development, survival, and drug resistance, but many researchers try to use them as cancer-specific
drug delivery or to detect cancer metastasis [84]. In 2019, Abello et al. labeled exosomes obtained from
mesenchymal stromal cells (MSCs) with gadolinium or with NIR fluorescent dyes, demonstrating that
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MSC exosomes actually accumulate in OS tumors, inhibiting human and mouse OS cell proliferation
in vitro in a dose-dependent way [85]. Moreover, due to the host defense properties of exosomes,
Rayamajhi et al. (2019) developed small EVs hybridized with liposomes, which due to their colloidal
stability, drug loading and pH-sensitive sustained drug release resulted to be a valid tool in tumor
targeted drug delivery [38]. Another research carried out by Qi et al. (2016) involved the development
of a dual-functional exosome-based superparamagnetic NP cluster. Data exhibit an enhanced cancer
targeting and tumor growth suppression of drug-loaded exosomes under an external magnetic
field, suggesting that the incorporation of magnetism in exosomes could expand their biomedical
application [86].
Novel formulation of chemotherapeutics also involved NPs, developed with the aim of optimizing
the pharmacokinetic profile, improving drug targeting specificity and reducing toxicity with the
maintenance of the efficacy [87]. In this perspective, in a recent study, Wu et al. (2017) functionalized
HA NPs with medronate (as a bone-targeting moiety) and JQ1, (a chemotherapeutic agent). Data showed
that JQ1-loaded HA NPs exhibit an interesting selectivity and prolonged drug release, being more toxic
to tumor cells rather than to primary fibroblasts, thanks to the presence of medronate that selectively
attacks and destroys cancer cells without negative effects on healthy fibroblasts with an inhibition of
OS cell migration from the tumor spheroids. [88].
With the aim of developing a local delivery of cisplatin to malignant solid tumors and to reduce its
toxic effects, in 2004, Barroug et al. developed a system based on NPs made of different type of apatitic
CaP. A better activity of the samples was obtained when cisplatin was adsorbed on carbonated apatite
and poorly crystallized HA with reduced side effects like loss of weight and kidney damage [89].
For the treatment of OS, liposomes are other drug delivery systems attracting the interest of
researchers which are frequently used to encapsulate DOX in order to obtain a target delivery and
reduce its toxic effects like cardiotoxicity and congestive heart failure. To deliver DOX in a specific
way to OS cells, it is necessary that liposomes could target to cell with surface receptors specific for
tumor cells but not for healthy ones. Previous studies found that a type of tyrosine kinases receptor,
called ephrin Alpha 2 surface receptor (EphA2) is highly upregulated on OS cells. The interaction
between EphA2 and its ligand (ephrinA1) leads to intracellular events such as proliferation, migration
and cell survival, that are important in tumorigenesis. For this reason, Haghiralsadat et al. (2017)
conjugated DOX-loaded liposomes with YSA, a 12-amino acid peptide, obtaining that the system
YSA-liposomes-DOX could be efficiently targeted to the human SaOs-2 OS cell line and that 31 days
are required before the complete release of DOX was reached, making these systems a potetial tool
for other cancers presenting an overexpression of EphA2 [90]. At a later stage (2018), to overcome
OS multidrug resistance, Haghiralsadat et al. used siRNA to target intracellular kinase MAPK8IP1
(JNK-interacting protein 1 [JIP1]) founding that JIP1 siRNA could restore chemosensitivity to DOX.
At the same time, the resulting system is stable with a high loading efficiency of DOX and siRNA and
shows strong cytotoxic effects OS cells but not to primary bone cells [91].
Another type of drug delivery system that could be useful in OS therapy is represented by
microspheres, which could be used as drug carrier matrices. In 2018, Liu et al. prepared CaP porous
microspheres loaded with DOX, which exhibit high drug-loading capability and an enhancement in
the inhibition of the proliferation of OS cells in vitro with a promotion of the enrichment of DOX in
OS cells. Furthermore, a great potential for OS drug delivery and osteogenic differentiation in bone
regeneration could be observed [92]. With the same purpose, Zhou et al. (2017) developed calcium
phosphate-phosphorylated adenosine (CPPA) hybrid microspheres to exploit the influence of adenosine
on bone metabolism and on bone cells differentiation of bone marrow cells. They obtained a system
with a high DOX-loading capacity and pH-sensitive drug release properties with an enhancement
of in vitro/in vivo therapeutic efficiency for different OS cell lines and subcutaneous tumors in nude
mice [93].
In some studies, CaPCs, used as potential carrier for therapeutic agents in orthopedic application,
revealed a sustained-release capacity higher than other bone cements. In 2011, Tanzawa et al. developed
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CaPCs containing the association of cisplatin plus caffeine which seemed to be effective in reducing
bone tumor growth probably by a sustained release of the drug and a mechanism of inhibition of DNA
repair [94].
Tani et al. (2006) investigated the feasibility of the use of DOX-loaded CaPCs as a postoperative
filler material able to release the antitumoral drug. It was found that the presence of DOX doesn’t
influence CaPCs strengths, although bone formation around the DOX-loaded CaPCs is slower than
CaPCs alone. Also, DOX effects can last longer, (until 15 days), but only DOX particles located on the
surface of CaPCs can be released, suggesting useful the induction of CaPCs degradation to maintain
the local concentration of DOX for a longer time [95].
Another two types of systems are described in literature: β-TCP beads and nanohybrids. In 2017
Hess et al. prepared β-TCP beads loaded with cisplatin and DOX and then incorporated in a HA
matrix scaffold. It seems that the co-delivery of cisplatin and DOX may yield strong synergy in the
efficacy with a higher response rate, as suggested by results which show a short cisplatin burst release,
while DOX release can last for up to 40 days. Moreover, the incorporation in the matrix could reduce
cytotoxicity of the co-loaded composites [96].
Gonçalves et al. (2013) developed Laponite®/DOX/alginate nanohybrids that are capable to
sustain drug delivery and exert a prolonged anticancer activity. DOX was loaded into pH-sensitive
biocompatible anionic Laponite® nanodisks coated with alginate to prevent drug burst release.
The results demonstrate several advantages of formulated systems like high entrapment efficiency
(80.8 ± 10.6%), pH-sensitivity, biocompatibility, and a sustained drug release behavior. Also,
Laponite®/DOX/alginate nanohybrids can be internalized by OS cell line (CAL-72) and show a
noticeable cytotoxicity to cancer cells higher than free DOX, making these nanohybrids excellent
platforms for drug delivery [97].
Notably, the various drug delivery nanocarriers designed for OS treatment, so far discussed, are still
at experimental stage and further studies are needed before clinical application. Certainly, among all,
a significant role seems to be played by CaP NPs or CaPCs/CaP beads or β-TCP nanoderivatives,
which are considered as interesting nanocarriers to bone tissues thanks to their biocompatibility and
their accumulation capacity in bone tissues. Nevertheless, as previously reported, currently the only
nanosystem approved by EMA for the treatment of OS is represented by liposomal non-pegylated
MTP-PE (Mepact®, Millennium, Cambridge, MA USA). Guidelines provide for the administration
through intravenous (I.V.) infusion over a period of 1 h. In Figure 2 the mechanism of action of MTP-PE
is shown. In vitro tests performed on human monocytes led to the death of allogenic and autologous
tumor cells, while in vivo experiments in murine models resulted in the inhibition of tumor growth [98].
3.3. Osteoporosis
Researchers have currently focused their attention on the development of innovative drug delivery
systems which can increase the drug access to the bones and obtain a controlled drug release in order
to maintain required drug concentration levels for a long period of time without reaching toxic level or
dropping below the minimum effective level [99]. Many studies concern the development of CaPCs
loaded with BPs in order to allow a local release of the drug which might effectively increase bone
implant stability. With this aim, Gong et al. designed CaP silicate cements (CaPSC) and calcium
silicate cements (CSC) loaded with risedronate (RA) to obtain biocompatible systems able to promote
osteoblast proliferation and to reduce the prevalence of osteoporosis in animal models [100,101].
Similarly, Jindong et al. developed CaPCs with different concentrations of ALN which exhibited a
drug release up to 21 days and a good biocompatibility [102,103]. Some studies also reported the use
of BMP-2 to enhance osteoinduction in bone substitutes, since the available combination of BMP-2
with CaPCs provides a slow release rate of the factor and has a long degradation period. For this
reason, in 2010, Li et al. developed a composite bone substitute with CaPCs with BMP-2-loaded
gelatin microspheres (BMP-2/GM/CaPCs). Results suggest that BMP-2/GM/CaPCs composite can
release more rhBPM-2 than the system without gelatin microspheres and it can accelerate the bone
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healing of osteoporosis in vivo. Furthermore, BMP-2/GM/CaPCs provides a better bone mineralization
after 45 days of implantation [104]. A problem which can occur during alloarthroplasty is represented
by infections. To overcome these troubles and try to fill the missing regions of bone and provide
mechanical strength, Tanaka et al. (2002) created a CaPC containing arbekacin sulfate and polylactic
acid (PLA) as an implant for the release of antibiotics. Data confirmed the hypothesis of this study,
for this reason, developed systems could be considered by the researches useful tools in bone filling
and stiffening [105].Nanomaterials 2020, 10, x FOR PEER REVIEW 14 of 34 
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Implants can be considered as an alternative drug delivery system in osteoporosis treatment.
A study carried out in 2018 by Liu et al. reported that biomimetically deposited CaP-based coatings of
prostheses could be considered as a vehicle for the targeted delivery of some growth factors. For this
reason, they investigated the release mechanism and the kinetics of a CaP-based implant-coatings
loaded with BMP-2 by use of a radiolabeled derivate (131I-BMP-2). The release of BMP-2 from the
depot appears to be characterized by a burst-release kinetic profile [106]. In 2014, Pyo et al. adopted
a biomimetic method to coat titanium implants with CaP incorporating different concentrations of
ZOL (8, 80, 800 µg/mL) to promote peri-implant bone formation in osteoporotic cases. The 800 µg/mL
treatment group exhibited the best results, showing bone around implants which were more similar to
typical plate-like trabecular bone and with ideal trabecular bone structure [107]. In 2005, Peter et al.
demonstrated the effectiveness of the use of a local BPs delivery (ZOL) from a CaP coating to increase
the mechanical fixation of an orthopedic implant. It resulted that the increase in peri-implant bone
density was ZOL concentration-dependent and that the ZOL release positively influenced the structure
of bone and, probably, the mechanical stability of the implant [108].
To reduce side effects connected with the systemic use of BPs in the treatment of osteoporosis,
different studies were focused on the development of CaP composite materials. For example, Forte et al.
(2017) functionalized octacalcium phosphate (OCP) with ALN and ZOL in order to obtain a good
compound suitable for local administration. Both drugs stabilize OCP by preventing the hydrolysis,
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but better results of bone cells viability and interaction with OCP structure were obtained with ZOL.
Both ZOL and ALN maintained their antiresorptive effects even when incorporated in OCP [109].
Some studies involved the use of CaP NPs as a potential carrier for the treatment of osteoporosis.
In 2013 Chen et al. developed trace elements (TEs)-codoped CaP particles and examined TE retention
and bone consolidation in osteoporotic animal models. In fact, it seems that TEs play a critical role in
the maintenance of hard tissue function due to their essential and nutritional effects [110]. Pareta et al.
(2008) developed iron oxide NPs evaluating their cytocompatibility with osteoblasts. Directing such
NPs to bone disease under an external magnetic field (MRI) could promote site-specific bone growth.
At a later stage, iron oxide NPs were coated with CaP in the presence of bovine serum albumin (BSA)
and citric acid (CA) to reduce particle aggregation and increase osteoblast density after one day [111].
Sometimes, scaffold could be considered as a valid alternative approach for the treatment of
osteoporosis. For example, the studies of Chou et al. (2016) were based on the implantation of
Foraminifera exoskeletons hydrothermally converted to β-TCP scaffold material for the delivery of
simvastatin which has been shown to promote bone regeneration. From their results it appeared that
β-TCP with or without simvastatin is able to induce bone formation in osteoporotic mice and that a
slower release of simvastatin could be obtained with drug-loaded scaffolds. However, further studies
are required to find the optimal concentration to induce therapeutic effects [112]. In 2015, Liporace et al.
observed the dose-dependent effect of local delivery of rhBMP-2 using a HA/TCP carrier. Two different
doses of rhBMP-2 were tested, exhibiting significantly higher bone mineral density than controls.
After eight weeks, better results were obtained with the high dose. Biomechanical tests revealed
dose-dependent trends in all samples with minimal significant differences [113].
Lastly, some articles found in literature reported the use of other drug carriers like nanodiamonds,
CaP nanocapsules, CaP matrix, microspheres and auto-forming gel as alternative tools in the treatment
of osteoporosis. Ryu et al. (2016) conjugated ALN onto a nanodiamond surface to obtain a synergistic
effect. Developed systems show a specific uptake and accumulation to bone tissue with an increment
of bone mechanical strength [114]. Ito et al. (2012) developed CaP-coated deoxycholate micelles
including simvastatin to obtain a delayed release of simvastatin which could reduce its side effects.
Actually, it appears that CaP encapsulation reduced the cytotoxicity in cultured cells and suppressed
inflammation leading to a whole-body therapeutic effect. For this reason, such biocompatible CaP
nanocapsule is expected to be a novel tool for the delivery of hydrophobic drugs [115].
In another study carried out by Ito et al. (2012), simvastatin was incorporated in an alginate
gel where highly amorphous calcium phosphate (ACP) was added as a buffering agent to avoid the
acidification of the gel-environment (Figure 3).
When injected in osteoporosis rat, a soft gel was formed in the injected site, providing a
continuous release of simvastatin under the acidic condition and exhibited high therapeutic effect
on the osteoporotic rat demonstrating that auto-forming alginate gel represents a novel controlling
device for the delivery of simvastatin [116]. In 2010, Kim et al. developed CaP microspheres which
were loaded with ALN during microsphere formation, providing a better drug loading and a simpler
fabrication process. Preliminary in vitro results show the potential of bioabsorbable CaP microspheres
in inhibiting osteoclast formation, making them a possible alternative to common oral formulations
which exhibit low bioavailability, undesirable GI effects, and need frequent administrations [117].
In 2010, an injectable BP-combined CaP matrix was developed with the aim of biologically
reinforcing osteoporotic bone incrementing bone fraction and improving bone micro-architecture.
The developed system is able to form new bone and to reinforce specific osteoporotic bone site
controlling the excessive resorption activity of osteoclasts. Altogether, an injectable carrier based on
calcium deficient apatite, which exhibits immediate mechanical properties, could be more suitable
than a suspension of calcium deficient apatite granules due to its worse rheological and mechanical
properties [118].
Overall, the high potential offered by nanotechnology for the improvement of orthopedic repair and
regeneration regards the possibility to ameliorate host bone-implant interaction. However, the safety
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concern of injectable materials represents the main prerequisite in order to apply nanotechnology for
the treatment of osteoporosis.
In addition, a number of new nanomaterials such as injectable hydrogels, NPs or nanocomposites
are currently under study by many researchers to optimize their biocompatibility, detecting,
and environment-responsive capabilities and drug loading efficiency.Nanomaterials 2020, 10, x FOR PEER REVIEW 16 of 34 
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Figure 3. Scheme representing the preparation of simvastatin-loaded alginate gel which becomes a soft
carrier after injection in mice. Amorphous calcium phosphate (ACP) acts like a buffer to avoid the
acidification of the gel-environment prolonging drug release.
3.4. Osteomyelitis
A pilot study was carried out by Rogers-Foy et al. in 1998 with the aim to investigate the possibility
of developing a drug delivery system that could both eradicate infection and provide a scaffold for
osseous integration. For this reason, they prepared two porous composite systems using HA as carrier
for GS to eradicate Staphylococcus aureus. Data confirm that the inclusion of GS into ceramic matrix
doesn’t affect osteointegration or bone apposition and that this type of system may be beneficial in the
treatment of infected osseous sites [119].
Lulu et al. (2018) investigated the efficacy of TOB-loaded CaP beads which can be adopted as a
standard care because they enable the localization of supra-MIC levels, difficult to achieve with other
substitutes. In fact, this system effectively promoted bone and soft tissue healing and prevented bacterial
colonization by Staphylococcus aureus. Furthermore, CaP beads show promising anti-staphylococcal
activity for the treatment of chronic osteomyelitis in association with TOB, with long period of sustained
efficacy [120].
Another tool in the treatment of osteomyelitis is represented by CaPCs. In 2016, Ghosh et al.
developed vancomycin-loaded and ciprofloxacin-loaded cements which comprised two synthesized
HA powders (HAP): HAP1 and HAP2 with four different weight ratios of HAP1/HAP2: 100/0,
85/15, 50/50 and 0/100. All types of formulated samples inhibited the growth of Staphylococcus aureus,
Escherichia coli, and Pseudomonas aeruginosa with results similar with those obtained with the antibiotic
per se (ciprofloxacin) or even larger than the vancomycin. The strong antibacterial effect and the
biocompatibility with osteoclasts exhibited even by pure cements are noteworthy. This is a highly
relevant insight in view of the rising resistance of some pathogens to traditional antibiotics [121].
For the treatment of methicillin-resistant Staphylococcus aureus (MRSA) Schnieders et al. (2011)
investigated the influence of porosity of CaP composites on the release of vancomycin through the
drug-encapsulation into biodegradable microspheres made of PLGA, which were added to CaPCs
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at different powder to liquid (P/L) ratios with the aim of obtaining cements with different porosities.
Results exhibited that the porosity of cement and the vancomycin release profile are both influenced by
variations in P/L ratio. In particular, vancomycin-HCl entrapment into PLGA polymer microspheres
reduced the influence of the porosity on the cement, while the antibiotic activity of the embedded
substance is maintained. Furthermore, after drug entrapment into PLGA matrix, the drug burst is
minimized and the drug release is prolonged [122]. Another approach for the eradication of chronic
osteomyelitis caused by MRSA was previously tested by Lazarettos et al. (2004). They developed a
CaPC enriched with 3% of teicoplanin which showed filler properties of bone defects through newly
growing host bone. From the results, it appeared that, due to their spongiform structure, these CaPCs
are able to incorporate a double amount of antibiotic in comparison with a solid acrylic material.
Furthermore, they exhibit good tissue compatibility, high released drug concentrations and flexibility
to the dose and the type of antibiotic that can be loaded into them avoiding reoperation for cement
removal [123]. For the prevention of osteomyelitis, Stallmann et al. (2004) developed hLF1-11-loaded
and GS-loaded CaPCs and described their efficacy, which was proven to be greater in presence of
HLF1-11 [124].
In 2004, Joosten et al. carried out a study in which they investigated the in vitro release
of hydroxyapatite cement (HAC) loaded with GS, its mechanical properties and in vivo efficacy.
Results suggest that neither the mechanical properties of HAC nor the antibiotic properties of GS were
affected when mixed in the concentrations range taken into account. A prolonged release of high levels
of GS is obtained with this system which allows a long-term antibacterial effectiveness in situ and
in vivo [125].
Another tool that has attracted the attention of researchers in last decades is represented by
antibiotic loaded particles and CaP-coated NPs which provide a bone-compatible surface (Figure 4).Nanomaterials 2020, 10, x FOR PEER REVIEW 18 of 34 
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nanoparticles (NPs) loaded with antibiotic. Negatively charged NPs could selectively bind Ca2+ ions
situated on bone surface.
With this aim, Bastari et al. (2014) developed and investigated the antibacterial activity of PLGA
particles coated with CaP. Tests were performed loading two antibiotics, nafcillin and levofloxacin,
which are conventional treatments for methicillin-sensitive Staphylococcus aureus (nafcillin) and
pathogens of chronic osteomyelitis (levofloxacin). A good drug loading efficiency (above 50%) was
achieved with both the antibiotics. Furthermore, in vitro tests showed a biphasic release characterized
by diffusion and degradation mechanism, confirming the aim of obtaining a sustained drug release up
to 4–6 weeks. Inhibition of biofilm formation and its deterioration also occurs [126].
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To overcome the burst release of small molecules from HA NPs, Uskokovic´ et al. (2014) coated the
drug-containing surface with chitosan, demonstrating that the embedment of 2–10 nm sized HA NPs
with chitosan mitigates the burst release of fluorescein (that is bound to HA) and promoted a release
time of three weeks. Furthermore, chitosan added to HA could inhibit the proliferation of osteoblastic
MC3T3-E1 cell line. However, important drawbacks of these systems concern their lower bacteriostatic
efficiency and unviable osteoblastic cell response to the composite material [127].
Previously, in 2013, Uskokovic´ and A. Desai developed agglomerates of NPs of CaP with various
monophasic contents. Then, CaP powders were loaded with small molecule drugs showing that
the sustained release of purposed systems was dependent on the degradation rate of CaP carriers.
Furthermore, through the combination of different CaP phases ratio, drug release profiles could be
tailored to the therapeutic occasion [128]. At a later stage, the same authors reported on the effect of
the previously synthesized CaPs on bacterial and osteoblastic cell cultures. All CaP powders showed
satisfying antibacterial activity against Staphylococcus aureus. Moreover, after the adsorption of the
antibiotic onto CaP particles, the deleterious effect that the free antibiotic exerted on the osteoblastic
cells was reversed, demonstrating that the material developed in the study could be considered
for alternative therapeutic approaches to prolonged antibiotic administration in the treatment of
osteomyelitis [129].
In 2018, Sampath Kumar et al. developed a dual mode antibiotic delivery system with antibacterial
ion substituted calcium deficient HA (CDHA) NPs. Doxycycline was chosen as antibiotic, because
it exhibits anti collagenase activity thereby preventing host mediated tissue destruction [130]. Then,
ions such as Zn, Ag, and Sr, were incorporated into CDHA, showing an initial high antibacterial
activity which can be extended by sustained ion release. Furthermore, AgCDHA and ZnCDHA exhibit
high antibacterial activity against Staphylococcus aureus and Escherichia coli, providing a potent tool
to treat incumbent drug resistant infection [131]. Another study carried out by Uskokovic´ et al. was
focused on a comparative analysis of two different nanocarriers of clindamycin with and without
PLGA coating. Both CaP particles show a positive response about the antibacterial performance of
the antibiotic-encapsulated powders against Sthaphylococcus aureus, while no cytotoxic or cytostatic
behavior resulted after the incubation of free antibiotic or any of the drug carriers with the osteoblastic
MC3T3-E1 cell line for up to three weeks. Future perspectives will aim at further enhancing the
osteogenic response of osteoblastic cells to these systems as well as the substitution of spherical CaP
particles with plate-shaped ones [132].
In 2012, Thanyaphoo et al. produced NPs of silicon (Si)-doped and then, they prepared bioactive
ceramics loaded with vancomycin, which is widely applied as a protection against staphylococcal
infections. Formulated systems showed a sustained release over a 12-day period that is sufficient for
killing Staphilococcus aureus growing as a biofilm, without toxicity to bone cells [133].
Considering most of the cited literature data on osteomyelitis topics, the combination of scaffold
for tissue regeneration of drugs, and especially with drug delivery systems, stands out as an emerging
and successful strategy to ameliorate osteomyelitis treatment, both to improve tissue regeneration and
to eradicate microbial infection.
Scaffolds/cements/nanodelivery composites, able to both modulate drug release and perform
osseous integration, are a smart and consolidated approach in the treatment of osteomyelitis and
represent an interesting therapeutic tool to improve antibiotic efficacy and, in some specific cases,
to overcome bacterial resistance.
3.5. Bone Regeneration
Currently, studies are mainly focused on the development of 3D composite scaffold and CaPs
composites, able to promote tissue regeneration and allow the controlled delivery of therapeutic drugs
included growth factors. Biocompatibility, nonimmunogenicity, and inertness to the normal bone
healings events are required for the materials used for drug carriers, that usually are composed of
natural/synthetic polymers or inorganic minerals. In the literature, different examples are reported,
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such as gelatin [134], collagen, hyaluronic acid, PEG, PLGA, CaP, HA, and β-TCP, (and also
polyphosphates as additives [135]), but in the case of natural polymers, there are some disadvantages
connected to their use, like immunogenicity, rapid degradability, and batch-to-batch variations. On the
other hand, synthetic polymers offers the possibility to be easily modified and processed to obtain the
suitable properties via the variation of their molecular weights, functional groups and/or structure [136].
Currently, CaPs, and in particular HA and TCP, are widely used in bone tissue engineering as bone
substitutes and drug carriers, for their biocompatibility, osteogenic properties and their similarities to
bone mineral with which they are able to form strong bonds [137].
In literature a great amount of studies reports the use of 3D porous scaffolds with drug delivery
capability for bone regeneration [138]. In 2018 Yao et al. developed mesoporous silica NPs (MSNPs)
incorporated in gelatin nanofibrous dual-drug delivery system to obtain a controlled release of
macromolecules like BMP-2 and deferoxamine. At the same time, this system, thanks to its excellent
bioactivity, could be useful to reduce high cytotoxicity, off-target effects and the short half-life of
deferoxamine. Results showed that the formulated scaffold could actually provide a controlled
dual-release at distinct release rate of both drugs loaded with the maintenance of their angiogenic and
osteogenic abilities [139].
In 2017, Song et al. developed an injectable cell-encapsulating alginate-fibrin hydrogel microfiber-CaPCs
tissue-engineered system. It resulted that the injectable construct is able to regenerate new bone in vivo
three-fold more than the control, with a quick degradation of the microfibers and release of the cells.
In addition, the system maintains its viability and osteogenic potential which make it interesting in
bone regeneration for several applications, like dental, craniofacial, and orthopedic surgeries [140].
In the same year, Frasca et al. carried out a study in which the bone healing process induced
with a porous pullulan/dextran-based hydrogel scaffold and a commercial HA/TCP ceramic (also in
association with mesenchymal stem cells) were compared, showing that the first system could be
considered as an alternative or complementary tool for its osteogenic properties, rapid resorption,
and capability to deliver growth factors [141].
Wang et al. (2016) encapsulated stem cells of different origins in alginate-fibrin hydrogel fibers,
which were then mixed with CaPCs paste to form an injectable system with fast setting time and high
porosity, and investigated which type of stem cells would be superior in osteogenesis. Results reveal
that formulated systems are able to enhance bone regeneration and that they could be used for dental
and orthopedic applications [142]. In 2015, Nazemi et al. studied the effect of adding PLGA NPs on a
chitosan-bioactive glass (chitosan-BG) scaffold revealing that the presence of NPs could increase the
mechanical strength of the scaffold, reducing its swelling behavior. Moreover, the addition of NPs makes
the system suitable to be implanted as a controlled-release platform of model drugs [143]. The aim of
the study carried out by Zhang et al. (2015) was to develop and to evaluate CaP composite scaffolds
containing simvastatin-loaded PLGA microspheres. Data analysis exhibits a certain biocompatibility and
osteogenesis in vitro and in vivo, improving the efficiency of new bone formation [144]. Another two
important works concerned the study of in vitro and in vivo behavior of PLGA/CaPCs scaffold with a
lamellar pore structure [145] and biphasic CaP scaffold loaded with ALN [146,147], which demonstrated
biocompatibility and effective osteogenesis, characteristics which make them potential tools for bone
tissue engineering in orthopedic and dental fields.
Hydrogel-based systems have several advantages such as the ability to provide a hydrophilic
environment suitable for new bone growth, the possibility to be tailored for a better geometry,
degradation rate and release profile [148]. Hydrogels can be produced with one or more-step methods
like polymerization or the synthesis of polymer molecules. Important factors which may influence
many of the properties of the hydrogel are the type and the degree of crosslinking [149]. A wide
variety of hydrogel formulations can be developed via different preparation methods. In literature,
for example, a recent study by Tangprasert et al. (2017) involved the development of a mimicked
extracellular matrix composed of gelatin/chitosan/CaP compounds in different ratio with the aim of
obtaining an ex-vivo model for the evaluation of tissue formation. Indeed, the results showed that
Nanomaterials 2020, 10, 875 20 of 35
formulated systems are similar to extracellular matrix of bone, as well as able to enhance cell viability
and proliferation [150].
To obtain an advantageous biomaterial for bone tissue engineering, Yu et al. (2016) drew up an
easy method to synthetize graphene hydrogels by self-assembling of graphene oxide, HA NPs and
chitosan into a 3D hydrogel. The resulting composite exhibits high mechanical strength and capacity to
binding HA, meeting the requirement of bone materials [151]. As an alternative to the use of autologous
tissues, two studies attracted our attention, one carried out by Weinand et al. (2006) and the second by
Schröder et al. in 2015. In the former case, researchers combined mesenchymal stem cells suspended in
hydrogels and 3D β-TCP scaffolds, obtaining a compound which can support bone formation in vitro
(especially in presence of collagen I hydrogel) [152]. In the latter case, Schröder et al. demonstrated
the promising characteristics of biodegradable PEG hydrogel loaded with vaterite (a polymorph of
CaCO3) NPs, stable enough to obtain a potential ion buffer for bone regeneration but also capable of
allowing the conversion of CaCO3 into HA. Evidence revealed the potential bone targeting capability
of this type of systems as well as a certain biodegradability. In this way the hydrogel would not
stay persistently in the body but could serve as a scaffold for the regeneration of new bone tissue.
Moreover, they don’t show any inflammatory potential [153]. A 2014 study by Douglas et al. provided
for the mineralization of gellan gum hydrogels by the incorporation of alkaline phosphatase in media
containing calcium and/or magnesium glycerophosphate at different ratios. Results demonstrated that
calcium is incorporated better than magnesium and that the rigidity of the compound is related to the
mineralization medium. Furthermore, when magnesium is incorporated into mineral, an increase in
osteoblast attachment and proliferation can be observed [154].
Hydrogels could be used also as bone-filling materials. In particular, Nonoyama et al. in 2012
prepared peptide hydrogels though the mineralization of ACP and HA, demonstrating that the above
mentioned systems have a viscoelastic strength sufficient to be injected and that the calcium ions are at
the same time a source of minerals and a reinforcing agent which can increase the mechanical strength of
hydrogels [155]. At the end, another noteworthy study for our purpose is that of Leeuwenburgh et al.
(2007) in which the researchers developed composite hydrogels in which CaP nanocrystals were
precipitated in presence of dissolved oligo(poly(ethylene glycol)fumarate) macromers, demonstrating
that, in this way, the swelling behavior of this compound can be reduced with an increment of its
cross-linking [156].
Another tool which possesses some advantages in the goal of bone regeneration medicine is
represented by NPs. For this purpose, Qu et al. (2016) drew up a multilayered coating made of PLGA
NPs, heparin and chitosan for the delivery of dexamethasone and rhBMP-2. It seemed that PLGA NPs
could be transported across the cell membrane improving the intracellular delivery of dexamethasone
through the internalization inside cells. In this way researches demonstrated the possibility of a
dual sustained release of dexamethasone and rhBMP-2 with a coating that could be combined with
others biomaterials enhancing their osteogenic properties [157]. Another study (2016) in the literature
involved the use of lithium modified BG NPs for the co-delivery of lithium ions and other drugs as a
possible treatment in a first instance for patients with osteomyelitis, osteoporosis, and bone cancer but,
later, also for bone engineering. Researchers obtained a prolonged release of loaded drug for 32 days
with a release profile depending on the concentration of the drugs loaded during the preparation of
the system [158].
Recently, microparticulate systems represent a valid tool for the treatment of defective bones
(e.g., implantation and maxillofacial treatment), thus different research involved the study of various
systems eventually loaded with bioactive drugs and/or molecules. For example, in 2011, Park et al.
developed microspheres composed of CaPCs incorporating biological proteins which can be released
in a sustainable way over a month. Adhesion and proliferation of the cells cultured upon microspheres
was observed, making these systems potentially useful as 3D matrix [159]. With the same purpose,
Ribeiro et al. (2004) prepared CaP-alginate and HA-alginate microspheres loaded with enzymes [160].
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On the other hand, CaPCs could represent a promising alternative for bone disease due to their
good bioactivity, osteoconductivity, injectability, and moldability. As mentioned above, they were
approved by FDA for the treatment of craniofacial defects and bone fractures (Figure 5) [161].
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Figure 5. Schematic representation of the advantageous characteristics of bone injected calcium
phosphate cements (CaPCs).
An interesting study found in literature (2016) reports the development of nanostrontium
HA-enhanced CaPCs and simvastatin-loaded PLGA microspheres plus CaPCs composite for increasing
bone formation. In fact, some studies confirm that strontium can stimulate osteoblast differentiation
and inhibit osteoclast activity. Results suggest that the strontium-CaPCs exhibit good biocompatibility
and induce higher bone regeneration, while strontium-CaPCs containing simvastatin-loaded PLGA
microspheres show higher levels of osteogenic differentiation. It appears that, in presence of
nanostrontium there is an improvement of the chemophysical properties of CaPCs with a reduction
of disturbances factor for the tissue like inflammation. Furthermore, in the presence of PLGA
microspheres loaded with simvastatin, better results were obtained in terms of osteogenesis compared
to strontium-CaPCs alone [162].
Finally, a good alternative is represented by HA-composites with reduced crystal dimensions in
order to obtain a hard tissue replacement. In 2006, Boanini et al., based on the evidence that ASP and
GLU play a role in bone cell signaling, explore the possibility to develop HA-ASP and HA-GLU crystal.
Results show that HA-ASP and HA-GLU nanocrystals are able to help the growth of MG63 cells in vitro
and promote their differentiation, by promoting osteoblast proliferation and metabolism/differentiation
activation [163]. More recently, in line with these findings, HA NPs loaded with both Mg2+ and Zn2+
ions were used to coat BG-based scaffolds of 45S5 composition and tested as materials for bone tissue
engineering applications [164]. These materials exhibited higher/faster bioactivity and an increase of
proliferation of MG-63 cells than uncoated scaffolds. In agreement with these results, SEM images
confirmed increased interaction between coated scaffolds and cells. Altogether, the obtained results
suggest that nanocrystalline Mg-Zn dopped-HA coatings may enhance the biological performance of
standard scaffolds of 45S5 BG composition.
From literature data on the topic, it emerges that CaPs such as HA play an important role due to
their similarity to bone mineral phase and to their osteoinductive properties.
Among the many cited systems in this paragraph, the authors think that CaP nanoparticulate
systems represent the strategy of the future, as they have been successfully used for the delivery of
several therapeutic factors for bone repair, comprised gene delivery.
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Further efforts should be made to fully understand and mimic the natural healing process of
bones, a mandatory requisite to develop the ideal CaP-based nanocomposite system.
4. Summary of the Commonest Drug Delivery Systems for Bone Diseases
A concise summary of the bone drug delivery studies examined in this review is reported in
Table 9. For this purpose, each drug delivery system is linked to its application field, main advantages
and disadvantages, and relative references.
Different types of drug delivery systems such as NPs, cements, scaffold and gel/hydrogels have
been recently exploited for the treatment of bone diseases. As represented in the diagram below
(Figure 6), among all the studies cited in this review, almost 54% consists in the above-mentioned
drug delivery systems (19%, 15%, 10%, and 10%, respectively). Such a trend is probably due to their
peculiarities, e.g., bioactivity, osteoconductivity and biocompatibility. Furthermore, several studies
demonstrated that a controlled and prolonged drug release could be obtained with these systems
which could also be tailored (by coating or changing of surface charge) in order to improve stability
and receptor binding, or to optimize the therapeutic effects.
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Table 9. Summary of the studies on bone drug delivery examined in this review.
System Applications Advantages/Disadvantages References
Beads OS
Carrier of low molecular weight drugs
Best results with alginate/chitosan association
Time-dependent, but burst and inconsistent release profile
Non-biodegradable, need to be surgical removed
[44,45,120]
Cements
Bone regeneration
Bone metastases
Osteoporosis
Osteomyelitis
OS
Ability to harden in vivo and to form bond with bone, low temperature setting reaction, excellent
bioactivity, osteoconductivity
Low strength, lack of full injectability, slow resorption rate, limited amount of incorporated drug,
heterogeneity of drug repartition
[50,51,83,94,95,100–105,
121–125,161,162]
Ceramics Osteomyelitis
Simple preparation, modifiable size and structure, desirable stability under physiological conditions,
low toxicity, good biocompatibility
High cost, low encapsulation, uncontrollable dose
[2,52,53,133,137]
Conjugates Bone metastasesOsteoporosis
Good aqueous solubility, stability and controlled delivery
Better oral bioavailability, tumor targeting, reduced toxicity for lipid-drug conjugates [48,49,77,79,80]
Dendrimers Bone metastases
Drug/oligonucleotides easily encapsulated
Monodisperse size, good water solubility
Modifiable surface
Markable cytotoxicity for cationic surface end groups
[47,73,75]
EVs OS Cargo of cellular content, drugs and biomolecules [38,39,84–86]
Gel Osteoporosis Controlled and continuous drug releaseHigh therapeutic effects, capable of auto-forming in situ [58,116]
Hydrogels Bone regeneration
Sol-gel transitions due to body temperature or pH variations
Possibility to be tailored for a better geometry, degradation rate and release profile
Development of a hydrophilic environment suitable for new bone growth, fast setting time
Suitable for dental and orthopedic applications
[142,148–156]
Implants Osteoporosis
Biocompatibility, prolonged drug release, tailored biodegradation kinetics
Suitable for cardiovascular, neuroprosthetic and orthopedic purpose
Required surgical procedures with some side effects like bleeding, infections or nerve injuries
(for dental implants)
High production costs and the possible presence of degradation fragments which impair new grown bone
[62,106–108,119]
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Table 9. Cont.
System Applications Advantages/Disadvantages References
Liposomes Bone metastasesOS
Good biocompatibility and loading properties
Possible prolonged/targeted drug delivery [40,71,72,90,91]
Matrices Osteoporosis Improved patient compliance, treatment efficiency, reduced costs, possibility to reduce drug administratedProbability of dose dumping, poor in vitro/in vivo correlations [59,118]
Nanocapsules Osteoporosis Protective coating which delays compounds release, high reproducibility, broad range of application [60,115]
Nanocrystals Bone regeneration Suitable for intravenously injection, slowly blood dissolution, improved biodistributionOpsonization could prolong circulating time, promote tumor accumulation, improve targeting efficiency [55,163]
Nanodiamonds Osteoporosis Large surface area, easiness surface functionalization, suitable as photoluminescent probesNegligible cytotoxicity, high biocompatibility [54,114]
Nanohybrids OS Capable to incapsulate drug with low water solubility, possible tool for non-invasive tumor targetingGood biocompatibility and biodegradability [56,57,97]
Nanoplatforms Bone metastasesOsteomyelitis
Biocompatible and biodegradable
Tunable size, changeable membrane permeability, possible bound with targeting ligand, capable to load
hydrophilic/lipophilic drugs
Responsive to pH, ionic strength, temperature
[30,31,64,81,82,143]
NPs
Bone regeneration
Bone metastases
Osteoporosis
Osteomyelitis
OS
High soluble, bioavailable
Possible surface coating or functionalization to improve stability and bone targeting
[32,43,46,65–70,87–89,
110,111,126–132,157,
158]
Scaffolds Bone regenerationOsteomyelitis
Biocompatible templates, promote attachment and growth of bone cells, induce osteogenesis
Possible drug carriers
[61,63,96,138–141,144–
147,164]
Spheres and
microspheres
Bone regeneration
Osteoporosis
Osteomyelitis
OS
Reduced side effects and improved efficiency of cytotoxic anticancer drugs
Alternative routes: ophthalmic, topical, nasal, intramuscular
Good choice for low/high molecular weight drugs, DNA fragments, peptides, proteins
[41,42,92,93,112,117,159,
160]
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5. Conclusions
Conventional therapies in the treatment of bone disease are still widely used although they exhibit
several disadvantages such as lack of patient compliance due to adverse reactions of administered
drugs and to the invasiveness and the low selectivity of the treatment.
In the last decades, nanotechnology has come to represent an attractive choice in order to overcome
these problems, mainly owing to the versatility of nanosystems that, if properly functionalized,
can selectively reach the site of bone disease and prolong drug release. A wide range of nanoscale
matrices, like polymers and ceramics, are the most used materials to produce these systems which can
be further improved by tailoring surface properties, for example with CaP, that exhibit characteristics
similar to bone components. A considerable part of these innovative delivery systems has been studied
at a preclinical level, indicating only a moderate positive effect for some of them, such that further
investigations are certainly required for clinical trials and following commercial purposes.
Evidently, not all drug delivery strategies are equally promising. Overall, compared to other
platforms, cements seem to provide more opportunities being the most versatile approach already
widely employed from OS to osteomyelitis and bone regeneration. In parallel, nanotechnologies have
demonstrated, mainly in preclinical trials, significant benefit in both targeting and prolonging drug
release. For these reasons, we believe that in the near future therapies combining bone cements,
especially HA and TCP, with drug loaded nanocarriers can offer a successful approach for the treatment
of bone diseases.
Undoubtedly, ongoing research and future perspectives will provide for the further improvement
of the characteristics and the selectivity of these systems.
Technologies such as quality-by-design, process analytical techniques and microfluidics could
significantly accelerate the translation of nanomedicines. Nevertheless, this kind of approach requires
further learning and an adequate regulatory background. Overall, to achieve an efficient clinical
translation, collaboration among academia, industry, and regulatory bodies is required to ensure safe
and effective nanomedicine products.
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ACP Amorphous calcium phosphate
ALN Alendronate
ASP Aspartic acid
Au@MSNPs Gold nanorods enclosed inside mesoporous silica nanoparticles
BG Bioactive glass
BMP Bone morphogenetic protein
Bip 3,5-di(ethylamino-2,2-bisphosphono) benzoic acid
BPs Bisphosphonates
BSA Bovine serum albumin
CA Citric acid
CaP Calcium phosphate
CaPCs Calcium phosphate cements
CaPSC Calcium phosphate silicate cements
CDHA Calcium deficient hydroxyapatite
CPNs Coordination polymer nanoparticles
CPPA Calcium phosphate-phosphorylated adenosine
CSC Calcium silicate cements
DOX Doxorubicin
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DSP Diamminedichlorosuccinate-platinum
DTPA Diethylenetriaminepentaacetic acid
DTX Docetaxel
EMA European Medicines Agency
EVs Extracellular vesicles
FDA Food and Drug Administration
FGF Fibroblast growth factor
GI Gastrointestinal
GLU Glutamic acid
GS Gentamicin sulfate
HA Hydroxyapatite
HAC Hydroxyapatite cement
HAP Hydroxyapatite powder
IGF Insulin-like growth factor
IL Interleukin
I.V. Intravenous
MA Monoethyl adipate
MMPs Matrix metalloproteinases
MRI Magnetic resonance
MRSA Methicillin-resistant Staphylococcus aureus
MSCs Mesenchymal stromal cells
MSNPs Mesoporous silica nanoparticles
MTP-PE Muramyl tripeptide phosphatidyl ethanolamine
MTX Methotrexate
N-BPs Nitrogen-containing bisphosphonates
NIR Near infrared
NPs Nanoparticles
OCP Octacalcium phosphate
OS Osteosarcoma
P/L Power to liquid
PAMAM Polyamidoamine
PDGF Platelet-derived growth factor
PEG Polyethylene glycol
PEPn Na Poly(ethylene sodium phosphate)
PL Plumbagin
PLA Polylactic acid
PLGA Poly(lactic-co-glycolic) acid
PMMA Poly(methyl methacrylate)
PNs Polymeric nanoparticles
PTH Parathyroid hormone
PTT Photothermal therapy
PTX Paclitaxel
RA Risedronate
RANKL Nuclear factor kappa-B ligand
ROS Reactive oxygen species
SERMs Selective estrogen receptor modulators
SPIONs Superparamagnetic iron oxide nanoparticles
TCP Tricalcium phosphate
TEs Trace elements
TGF-β Transforming growth factor-β
TNF Tumor necrosis factor
TOB Tobramycin
TSECs Tissue-selective estrogen complexes
VEGF Vascular endothelial growth factor
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VEGFR Vascular endothelial growth factor receptor
W/O Water in oil
ZOL Zoledronate
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